Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

Gastroenterology

Volumn 119, Issue 6, 2000, Pages 1473-1482

  Fedorak, Richard N ^a,a   Gangl, Alfred ^b   Elson, Charles O ^c   Rutgeerts, Paul ^d,d   Schreiber, Stefan ^e,e   Wild, Gary ^f,f   Hanauer, Stephen B ^g   Kilian, Ann ^h   Cohard, Marielle ^h   LeBeaut, Alexandre ^h   Feagan, Brian ⁱ   Gasche, Christoph ^b   Hanauer, Steven B ^g   Hanauer, Charles A ^j   Wilson, John H P ^k   Tilg, Herbert ^l   Isaacs, Kim ^m   Jacyna, Meron ⁿ   Colombel, Jean Frederic ^o   Van Deventer, Sander J H ^p   Wright, John P ^q   Irvine, Jan ^r   Levine, Douglas S ^s   Tremaine, William J ^t   Lashner, Bret A ^u   Warner, Andrew S ^v   Mayer, Lloyd F ^w   Koningsberger, Jacob C ^x   Van Gossum, Andre ^y   Befrits, Ranger ^z   Deusch, Kai ^aa   Targan, Stephen ^ab   Gibson, Peter ^ac   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j UNIVERSITY OF FLORIDA   (United States)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l University Clinic for Internal Medicine III Cardiology and Angiology   (Austria)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

ⁿ NORTHWICK PARK HOSPITAL   (United Kingdom)

^o Hopital Claude Huriez   (United Kingdom)

^p ACADEMIC MEDICAL CENTER   (Netherlands)

^q Kingsbury Hospital   (United Kingdom)

^r MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^s UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^t MAYO CLINIC   (United States)

^u LERNER RESEARCH INSTITUTE   (United States)

^v LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^w MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^x UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^y ERASME HOSPITAL   (Belgium)

^z KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^aa UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^ab Cedar Sinai Medical Center   (Germany)

^ac ROYAL MELBOURNE HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; MESALAZINE; PLACEBO; RECOMBINANT INTERLEUKIN 10;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOCYTOPENIA;

EID: 0034463305     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.20229     Document Type: Article

References (24)

1. Enhanced mucosal cytokine production in inflammatory bowel disease
2. Cytokines in intestinal inflammation: Pathophysiology and clinical considerations
3. T cells in inflammatory bowel disease: Protective and pathogenic roles
4. Two types of mouse T helper cell, IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
5. Interleukin-10 deficient mice develop chronic enterocolitis
6. Interleukin-10 gene knockout mice; a model of chronic inflammation
7. - T cells
8. The basis of current and future therapy for inflammatory bowel disease
9. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease
10. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
11. Development of a Crohn's disease activity index. National Cooperative Crohr's Disease Study
12. Development of validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study
13. A new measure of health status for clinical trials in inflammatory bowel disease
14. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
15. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: Clinical and immunomodulatory effects
16. Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers
17. Recombinant interleukin 10 in subjects with active rheumatoid arthritis: A phase I and cytokine response study
18. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL4 and IL13
19. Development of anemia during anti-inflammatory treatment for Crohn's disease with rhu interleukin 10
20. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
21. Safety and tolerance of subcutaneous recombinant human interleukin-10 in subjects with Crohn's disease after first ileal or ileocolonic resection
22. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
23. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis
24. Anti-inflammatory effects of interleukin 10 in mild to moderate Crohn's disease